• 1
    Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J. Urol. 2002; 167: 52834.
  • 2
    Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 144551.
  • 3
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 8438.
  • 4
    Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol. 1993; 150: 11014.
  • 5
    Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J. Urol. 2001; 165: 15628.
  • 6
    Perrotti M, Pantuck A, Rabbani F, Israeli RS, Weiss RE. Review of staging modalities in clinically localized prostate cancer. Urology 1999; 54: 20814.
  • 7
    Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery – what we have learned and where we are going. J. Urol. 1999; 162: 293306.
  • 8
    Furuya Y, Ohta S, Sato N et al. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels. Anticancer Res. 2001; 21: 131720.
  • 9
    Graefen M, Karakiewicz PI, Cagiannos I et al. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J. Urol. 2002; 167: 13069.
  • 10
    Hara I, Miyake H, Hara S et al. Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int. 2001; 88: 537.
  • 11
    Kurita Y, Suzuki A, Masuda H, Ushiyama T, Suzuki K, Fujita K. Transition zone volume -adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels. Eur. Urol. 1998; 33: 328.
  • 12
    Melchior SW, Noteboom J, Gillitzer R, Lange PH, Blumenstein BA, Vessella RL. The percentage of free prostate-specific antigen does not predict extracapsular disease in patients with clinically localized prostate cancer before radical prostatectomy. BJU Int. 2001; 88: 2215.
  • 13
    Morote J, Encabo G, de Torres IM. Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur. Urol. 2000; 38: 2259.
  • 14
    Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J. Urol. 1998; 159: 123842.
  • 15
    Thiel R, Pearson JD, Epstein JI, Walsh PC, Carter HB. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. Urology 1997; 49: 71620.
  • 16
    Tombal B, Querton M, de Nayer P et al. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. Urology 2002; 59: 25660.
  • 17
    Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/mL. J. Urol. 1998; 160: 208995.
  • 18
    Horiguchi A, Nakashima J, Horiguchi Y et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate 2003; 56: 239.
  • 19
    Egawa S, Arai Y, Tobisu K et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis. 2000; 3: 26974.
  • 20
    D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N. Engl. J. Med. 2004; 351: 12535.
  • 21
    Nakashima J, Tanimoto A, Imai Y et al. Endorectal MRI for prediction of tumor site, tumor size, and local extension of prostate cancer. Urology 2004; 64: 1015.
  • 22
    Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol. Clin. North Am. 1993; 20: 66570.
  • 23
    Cornud F, Flam T, Chauveinc L et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 2002; 224: 20310.
  • 24
    Ikonen S, Karkkainen P, Kivisaari L et al. Magnetic resonance imaging of prostatic cancer: does detection vary between high and low Gleason score tumors? Prostate 2000; 43: 438.
  • 25
    Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy. J. Urol. 1997; 158: 18768; discussion 8–9.